International Assets Investment Management LLC acquired a new stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 935 shares of the company’s stock, valued at approximately $86,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in PPH. Almanack Investment Partners LLC. acquired a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter worth approximately $225,000. WT Wealth Management raised its holdings in VanEck Pharmaceutical ETF by 11.7% during the fourth quarter. WT Wealth Management now owns 39,613 shares of the company’s stock worth $3,223,000 after buying an additional 4,155 shares during the last quarter. Independent Advisor Alliance lifted its stake in shares of VanEck Pharmaceutical ETF by 100.8% in the fourth quarter. Independent Advisor Alliance now owns 98,473 shares of the company’s stock valued at $7,939,000 after buying an additional 49,423 shares in the last quarter. Gladstone Institutional Advisory LLC acquired a new position in shares of VanEck Pharmaceutical ETF during the fourth quarter valued at about $3,818,000. Finally, Trexquant Investment LP bought a new stake in shares of VanEck Pharmaceutical ETF during the fourth quarter worth about $504,000.
VanEck Pharmaceutical ETF Price Performance
PPH opened at $99.08 on Wednesday. VanEck Pharmaceutical ETF has a fifty-two week low of $74.05 and a fifty-two week high of $99.51. The firm has a market capitalization of $667.80 million, a PE ratio of 21.04 and a beta of 0.72. The company’s 50-day moving average is $94.12 and its 200 day moving average is $91.07.
VanEck Pharmaceutical ETF Cuts Dividend
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- When to Sell a Stock for Profit or Loss
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Compound Interest and Why It Matters When Investing
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.